GM-CSF as a therapeutic target in inflammatory diseases.
- Author(s)
- van Nieuwenhuijze, A; Koenders, M; Roeleveld, D; Sleeman, MA; van den Berg, W; Wicks, IP;
- Details
- Publication Year 2013-12,Volume 56,Issue #4,Page 675-682
- Journal Title
- Molecular Immunology
- Publication Type
- Journal Article
- Abstract
- GM-CSF is a well-known haemopoietic growth factor that is used in the clinic to correct neutropaenia, usually as a result of chemotherapy. GM-CSF also has many pro-inflammatory functions and recent data implicates GM-CSF as a key factor in Th17 driven autoimmune inflammatory conditions. In this review we summarize the findings that have led to the development of GM-CSF antagonists for the treatment of autoimmune diseases like rheumatoid arthritis (RA) and discuss some results of recent clinical trials of these agents.
- Publisher
- Elsevier
- Keywords
- GM-CSF ; Autoimmunity ; Inflammatory disease ; Rheumatoid arthritis ; Cytokines ; Autoimmune disease ; GM-CSF receptor ; Th17 pathway ; T cells
- Research Division(s)
- Inflammation
- Publisher's Version
- https://doi.org/10.1016/j.molimm.2013.05.002
- Terms of Use/Rights Notice
- Copyright © 2013 Elsevier Ltd. All rights reserved.
Creation Date: 2013-12-01 12:00:00